Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity
Dongyang Li, Yuhuan Jiao, Kun Wu, Hongyun Ma, Qianqian Hong, Liangzhi Xie
Elsevier ·
2026-12-01
· DOI 10.1016/j.curtheres.2026.100848
The publisher did not provide an abstract — full text is available via the link below.
Dongyang Li, Yuhuan Jiao, Kun Wu, Hongyun Ma, Qianqian Hong, Liangzhi Xie. Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity. // Current Therapeutic Research. – 2026. – DOI: 10.1016/j.curtheres.2026.100848. – URL: https://doi.org/10.1016/j.curtheres.2026.100848
Dongyang Li, Yuhuan Jiao, Kun Wu, Hongyun Ma, Qianqian Hong, & Liangzhi Xie (2026). Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity. Current Therapeutic Research. https://doi.org/10.1016/j.curtheres.2026.100848
Dongyang Li, et al. “Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity.” Current Therapeutic Research, 2026. doi:10.1016/j.curtheres.2026.100848.
@article{Li2026,
title = {Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity},
author = {Li, Dongyang and Jiao, Yuhuan and Wu, Kun and Ma, Hongyun and Hong, Qianqian and Xie, Liangzhi},
journal = {Current Therapeutic Research},
year = {2026},
doi = {10.1016/j.curtheres.2026.100848},
url = {https://doi.org/10.1016/j.curtheres.2026.100848}
}